Results 181 to 190 of about 81,958 (262)

Clinical Advances in Breast Cancer: A Comprehensive Overview of Full‐Course Disease Management

Cancer Innovation, Volume 5, Issue 4, August 2026.
This review provides a comprehensive overview of clinical advances in breast cancer, highlighting subtype‐specific therapeutic paradigms. It underscores the full‐cycle integration of innovative therapies, as well as the growing role of biomarker‐guided strategies in advancing precision medicine.
Xuenan Peng, Yujing Tan, Fei Ma
wiley   +1 more source

Correction: Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor.

Elife
Liu Q, Xiao Q, Sun Z, Wang B, Wang L, Wang N, Wang K, Song C, Yang Q.   +8 more
europepmc   +1 more source

Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ovarian cancer (OC) remains a lethal gynecological malignancy with challenges in early diagnosis, treatment monitoring, and overcoming drug resistance. Liquid biopsy, a noninvasive approach analyzing tumor‐derived components in bodily fluids, has emerged as a promising tool in OC management.
Jingxia Zhang, Weiyan Shan, Jie Yu, Huan Shi, Qiaoping Xu, Hongkai Shang   +5 more
wiley   +1 more source

Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1. [PDF]

Molecules
Morgan I, Rennert R, Berger R, Hassanin A, Davari MD, Eisenschmidt-Bönn D, Wessjohann LA.   +6 more
europepmc   +1 more source

Survival Impact of Programmed Cell Death Ligand‐1 Expression in Patients With Epithelial Ovarian Carcinoma

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Aims To evaluate the proportion of expressed programmed cell death ligands‐1 (PD‐L1) in epithelial ovarian carcinoma patients, and the association with the clinicopathological, surgical outcomes, and oncologic outcomes. To compare PD‐L1 protein expression with messenger ribonucleic acid (mRNA) expression. Methods The patients who had pathology
Achjima Tankul, Suchanan Hanamornroongruang, Naravat Poungvarin, Rachawalan Suriyasaengsri, Sompop Kuljarusnont, Pornprom Ittiamornlert, Wathirada Karnchanabanyong, Irene Ruengkhachorn, Saowalak Hunnangkul   +8 more
wiley   +1 more source

Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer. [PDF]

Front Oncol
Uekusa R, Yokoi A, Watanabe E, Inoue M, Mizuno K, Yoshida K, Yoshikawa N, Niimi K, Suzuki S, Kajiyama H.   +9 more
europepmc   +1 more source

SMAD4 Expression and Its Association With Treatment Resistance and Clinical Outcomes in Oral Squamous Cell Carcinoma Treated With Preoperative Chemoradiotherapy

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Small mothers against decapentaplegic homologue 4 (SMAD4) plays an important role in transforming growth factor (TGF)‐β signaling and is associated with various cancers. However, little is known about SMAD4 expression in oral squamous cell carcinoma (OSCC).
Junki Sakata, Akiyuki Hirosue, Ryoji Yoshida, Yuichiro Matsuoka, Yusei Todoroki, Hidetaka Arita, Hikaru Nakashima, Tatsuro Yamamoto, Nozomu Takahashi, Masatoshi Hirayama, Kenta Kawahara, Ryo Toya, Ryuji Murakami, Takaaki Ito, Yoshikazu Kuwahara, Hideki Nakayama   +15 more
wiley   +1 more source

Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]

J Ovarian Res
Zhang B, Lv W, Fu Z, Zhou Y, Du J, Yao Q, Qian Q, Bu H.   +7 more
europepmc   +1 more source

Genomic, Trop‐2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Ovarian carcinosarcoma (OCS) is a rare, aggressive tumor composed of both carcinomatous and sarcomatous components, typically associated with poor prognosis. Due to its rarity, the molecular characteristics, immune microenvironment, and optimal treatment of OCS remain unclear.
Tomomi Sakamaki, Tatsuyuki Chiyoda, Kohei Nakamura, Reika Takamatsu, Ryutaro Kawano, Daisuke Ochiai, Mitsuyo Jisaka, Mio Takahashi, Takuma Yoshimura, Yumiko Kimura, Shinya Oki, Kensuke Sakai, Tomoko Yoshihama, Hiroshi Nishihara, Wataru Yamagami   +14 more
wiley   +1 more source

Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma. [PDF]

BMC Cancer
Toyohara Y, Sone K, Kumegawa K, Yamamoto Y, Hachijo R, Kukita A, Taguchi A, Ikemura M, Miyamoto Y, Tanikawa M, Iriyama T, Mori M, Hamamoto R, Ushiku T, Oda K, Hirota Y, Maruyama R, Osuga Y.   +17 more
europepmc   +1 more source